Schizophrenia: elevated mRNA for dopamine D2(Longer) receptors in frontal cortex.

Article Details

Citation
Copy to clipboard

Tallerico T, Novak G, Liu IS, Ulpian C, Seeman P

Schizophrenia: elevated mRNA for dopamine D2(Longer) receptors in frontal cortex.

Brain Res Mol Brain Res. 2001 Mar 5;87(2):160-5.

PubMed ID
11245917 [ View in PubMed
]
Abstract

Because dopamine D2 receptors are the primary targets for antipsychotic drugs, including clozapine and quetiapine, and because some studies have found D2 receptors to be elevated in schizophrenia, we examined the mRNA of three forms of the D2 receptor, particularly the new form of the dopamine D2 receptor, D2(Longer), in post-mortem brains from patients who died with schizophrenia. Using quantitative competitive RT-PCR (reverse transcriptase-polymerase chain reaction), the D2(Longer) mRNA was higher in the frontal cortex, compared to control tissues. The mRNA concentration of D2(Long) and D2(Short) was also higher in the frontal cortex, compared to control tissues. Although most of the schizophrenia patients had received different antipsychotic drugs for varying periods of time, the mRNA of D2(Longer), as well as that for D2(Long) and D2(Short), in such medicated tissues was similar to that in a frontal cortex tissue from a patient who had reliably never received antipsychotic drugs. It is possible, therefore, that the elevation of the mRNAs for D2(Longer), D2(Long) and D2(Short) in the frontal cortex may be related to the disease of schizophrenia itself.

DrugBank Data that Cites this Article

Drugs